By
Francesca Gan and Chawanzi Chintu 
Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
| May Rank | April Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 9,960 | 956 | 41 |
| 2 | 2 | Johnson & Johnson | 1,532 | 666 | 124 |
| 3 | 3 | AstraZeneca | 873 | 291 | 23 |
| 4 | 5 | Abbott | 832 | 551 | 62 |
| 5 | 4 | GSK | 510 | 187 | 38 |
| 6 | 6 | Gilead Sciences | 465 | 64 | 4 |
| 7 | 7 | Roche | 392 | 172 | 51 |
| 8 | 8 | Novartis | 381 | 276 | 51 |
| 9 | 16 | AbbVie | 265 | 229 | 14 |
| 10 | 13 | Sanofi | 254 | 155 | 28 |
| 11 | 11 | Bayer | 241 | 98 | 15 |
| 12 | 9 | Lilly | 229 | 176 | 7 |
| 13 | 15 | Novo Nordisk | 221 | 191 | 20 |
| 14 | 14 | Merck & Co | 208 | 181 | 31 |
| 15 | 19 | Takeda | 205 | 200 | 15 |
| 16 | 10 | Biogen | 138 | 57 | 0 |
| 17 | 12 | BMS | 137 | 125 | 10 |
| 18 | 20 | Boehringer Ingelheim | 109 | 74 | 29 |
| 19 | 24 | Teva | 98 | 82 | 25 |
| 20 | 23 | Regeneron | 94 | 30 | 4 |
| 21 | 18 | Amgen | 89 | 54 | 8 |
| 22 | 17 | Fresenius | 87 | 57 | 15 |
| 23 | 32 | Daiichi Sankyo | 73 | 38 | 6 |
| 24 | 31 | Servier | 67 | 44 | 3 |
| 25 | 26 | UCB | 65 | 54 | 17 |
| 26 | 22 | Otsuka | 61 | 9 | 0 |
| 27 | 25 | Merck KGaA | 55 | 49 | 29 |
| 28 | 34 | Ipsen | 49 | 35 | 9 |
| 29 | 29 | Chugai | 34 | 1 | 1 |
| 30 | 33 | Allergan | 26 | 3 | 0 |
| 31 | 28 | Bausch | 25 | 5 | 3 |
| 32 | 27 | Eisai | 19 | 10 | 1 |
| 33 | 35 | Alexion | 17 | 11 | 1 |
| 34 | 39 | Mylan | 16 | 1 | 0 |
| 35 | 30 | CSL | 15 | 12 | 5 |
| 36 | 21 | Astellas | 12 | 5 | 1 |
| 37 | 36 | Grifols | 10 | 0 | 0 |
| 38 | 37 | Vertex | 9 | 6 | 0 |
| 39 | 38 | Menarini | 6 | 1 | 0 |
| 40 | 41 | Mitsubishi Tanabe Pharma | 4 | 3 | 1 |
| 41 | 40 | Sun | 1 | 1 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
| 50 | 50 | Ono | 0 | 0 | 0 |
| 50 | 50 | Endo | 0 | 0 | 0 |
| 50 | 50 | Meiji | 0 | 0 | 0 |
| 50 | 50 | Yunnan Baiyao | 0 | 0 | 0 |
| 50 | 50 | Aurobindo | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Sumitomo Dainippon | 0 | 0 | 0 |
The latest insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by healthcare professionals (HCPs) on Twitter during April 2022 were Pfizer, Johnson & Johnson, AstraZeneca, Abbott and GSK.
CREATION.co identified a 30% increase in mentions of pharmaceutical companies by HCPs this month compared to last month, increasing from 13,006 to 16,943 posts. Conversations continued to revolve around COVID-19 vaccine efficacy with HCPs sharing opinions following the release of FDA requested Pfizer vaccine documents, as well as news about side effects and the efficacy of AstraZeneca’s vaccine. Abbott also rose one spot in the ranking due to the widespread news of their infant formula recall.
80,000 pages of Pfizer documents dumped today AND its real bad…
— DoctorTro (@DoctorTro) May 5, 2022
Today the FDA Commissioner admitted the FDA failed to rapidly assess the Abbott manufacturing concerns. This delay ultimately resulted in the country scrambling for formula and requiring international aid. Supply chain issues & over-utilization of formula intensified the crisis.
— Nicole Saphier, MD (@NBSaphierMD) May 25, 2022
The top shared links by HCPs discussed multiple issues surrounding COVID-19 vaccines:
- A news article from the Telegraph about the possible side effects of AstraZeneca’s COVID-19 vaccine.
- An ICAN Archive about Pfizer’s vaccine data from the FDA’s FOIA Litigation.
- A news article from the Washington Post about the effectiveness of Pfizer’s COVID-19 shot in younger children.
The prominent driver of conversation in May 2022 came from HCP discussions of the release of the Pfizer documents at the beginning of the month. HCPs celebrated the successful approval of the Pfizer vaccine in children aged 6 months to 5 years. As trial data showed a strong immune response in the children who participated with preliminary data evidencing about 80% efficacy against Omicron.
Three-dose Pfizer Covid-19 vaccine produces strong immune response in 6 month-5 year old children. This is long-awaited news but when approved, will parents vaccinate their kids? To date only 35% of 5-11 yo have received at least one dose of vaccine. https://t.co/6Mbh4iOUhr
— Jonathan Reiner (@JReinerMD) May 23, 2022
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology notes:
- In April 2022, CREATION Pinpoint® identified 16,943 healthcare professional (HCP) authored tweets from 5,363 individual HCPs mentioning a Top 50 Pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 May and 31 May 2022.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In May 209 of these posts mentioned Janssen.
The Top 50 Pharma tracker archive
April 2022: HCPs celebrate the success of Lilly’s tirzepatide for obesity and discuss COVID-19 vaccine efficacy
March 2022: HCPs compare immune responses of T cell, B cell, and Antibodies to different COVID-19 vaccines.
February 2022: HCPs discuss Healthcare inequity and vaccination of under 5 year olds
January 2022: HCPs get political when discussing Regeneron’s COVID-19 treatment
December 2021: Omicron variant dominates HCP conversation in December 2021
November 2021 : HCPs discuss trial data of Pfizer’s COVID-19 booster vaccine and oral treatment
October 2021 : Pfizer most discussed company with booster and children’s COVID-19 jabs
